In a statement released March 10, Novo Nordisk said it initially received inspectional observations from the FDA in February 2025, and that it has been working diligently to address those observations ever since. In the statement on Tuesday, the drugmaker acknowledged it received the warning letter and that it welcomes further dialogue with the US FDA. The company said it is working diligently to address the concerns of the FDA
The Precision Peptide Genetic Test is $298 and provides actionable insights into peptide-pathway sensitivity that guide medication selection
Yes, youll need to start treatment at the lowest dose, regardless of your health status or starting weight
Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis
529 In a UC mouse model, astragalus polysaccharides similarly regulate the levels of inflammatory factors and oxidative stress to alleviate the inflammatory response and oxidative stress in mice, maintain the integrity of the intestinal mucosal barrier, and alleviate intestinal tissue damage
No, pregnant women should not take GLP-1 medications after a miscarriage or during any pregnancy